Conference Details - Agenda
View all Conferences
This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
Continuing Education Information
Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
Sixth International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
The Ritz-Carlton New York, Battery Park
New York, NY
March 20-21, 2009
Friday, Mar 20, 2009
| 7:30 am | Registration and Continental Breakfast |
| 8:00 am | Welcome, Introductions, and Presession Survey |
| Ovarian Cancer Debates Moderator: Marcus Randall |
|
| Debate 1: Intraperitoneal or Intravenous Chemotherapy? |
|
| 8:15 am | Intraperitoneal Chemotherapy Robert Coleman |
| 8:30 am | Intravenous Chemotherapy Eric L. Eisenhauer |
| 8:45 am | Rebuttal Robert Coleman |
| 8:50 am | Panel Discussion |
| Debate 2: Patients With Recurrent Advanced Ovarian Cancer Should Be Treated With Antiangiogenic Agents in Combination With Chemotherapy |
|
| 9:00 am | PRO Robert A. Burger |
| 9:15 am | CON Paul Sabbatini |
| 9:30 am | Rebuttal Robert A. Burger |
| 9:35 am | Panel Discussion |
| Debate 3: Secondary Surgical Debulking Is an Acceptable Option in Patients With Recurrent Platinum-Sensitive Ovarian Cancer |
|
| 9:45 am | PRO Larry Copeland |
| 10:00 am | CON J. Tate Thigpen |
| 10:15 am | Rebuttal Larry Copeland |
| 10:20 am | Postsession Survey and Panel Discussion |
| 10:40 am | Break |
| Ovarian Cancer Case Presentations and Discussion Moderator: Moderator: J. Tate Thigpen |
|
| 11:00 am | Clinical Scenario Presentations and Panel Discussion |
| 12:00 pm | Lunch |
| Translational Research in Ovarian and Endometrial Cancers Moderator: Michael Birrer |
|
| 1:00 pm | Clinical Implications of BRCA Testing Beth Karlan |
| 1:20 pm | Personalized Medicine: When and Why? Michael J. Birrer |
| 1:40 pm | Question-and-Answer Session |
| 1:50 pm | Overcoming Platinum Resistance Stephen B. Howell |
| 2:10 pm | New Agents for Platinum-Resistant Disease Robert Coleman |
| 2:30 pm | New Developments in the Biology of Endometrial Cancer Eric L. Eisenhauer |
| 2:50 pm | Question-and-Answer Session |
| 3:00 pm | Panel Discussion |
| 3:20 pm | Break |
| Ovarian Cancer Debate Moderator: Larry Copeland |
|
| 3:35 pm | Presession Survey |
| Debate 4: All Patients at High Risk for Ovarian Cancer Should Undergo Routine Screening |
|
| 3:40 pm | PRO Beth Karlan |
| 3:55 pm | CON Michael J. Birrer |
| 4:10 pm | Rebuttal Beth Karlan |
| 4:15 pm | Postsession Survey and Panel Discussion |
| 4:30 pm | Adjourn |
Educational Grants
An educational grant for this activity was provided by:
- Eli Lilly and Company
- Genentech BioOncology
- Centocor Ortho Biotech Inc.
- GlaxoSmithKline
- Bristol-Myers Squibb
- ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company
- sanofi-aventis U.S.